U.S. Senator’s Amendment Would Limit Drugmakers’ Prices Of Medicines Developed With Defense Department Funding
STAT: A proposal would limit prices on meds developed with Defense Department dollars
“A U.S. senator is trying to lower prices for medicines that are discovered with taxpayer dollars, and his effort amounts to a new twist to unraveling a complicated controversy that has embroiled the U.S. Department of Defense, large drug makers, numerous lawmakers, and consumer groups. Late last month, Angus King (I-Maine) successfully added an amendment to a Defense Department funding bill that consumer groups say would effectively allow an end run around drug makers that priced products — which were developed with taxpayer dollars — higher than what is charged in seven other countries. The trigger would be determined by median prices and per capita income compared with the U.S…” (Silverman, 7/6).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.